BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34255921)

  • 21. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
    Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
    Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
    Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
    Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
    Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
    Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
    Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S
    Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations.
    Sejben A; Pancsa T; Tiszlavicz L; Furák J; Paróczai D; Zombori T
    Thorac Cancer; 2023 Apr; 14(10):857-863. PubMed ID: 36808895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant pleural mesothelioma in a patient with pneumothorax: A cumbersome subtype both clinically and pathologically.
    Fukui T; Okubo T; Tanimoto N; Okuma H; Shiina Y; Kohama M; Yamada J; Funada Y; Ikura Y
    Thorac Cancer; 2021 Mar; 12(6):974-977. PubMed ID: 33533198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
    Zauderer MG; Bott M; McMillan R; Sima CS; Rusch V; Krug LM; Ladanyi M
    J Thorac Oncol; 2013 Nov; 8(11):1430-3. PubMed ID: 24128712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
    Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
    Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
    Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
    Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelioid pleural mesothelioma concurrently associated with miliary pulmonary metastases and minimal change nephrotic syndrome - A hitherto undescribed case.
    Tsukamoto Y; Otsuki T; Hao H; Kuribayashi K; Nakano T; Kida A; Nakanishi T; Funatsu E; Noguchi C; Yoshihara S; Kaku K; Hirota S
    Pathol Res Pract; 2015 Dec; 211(12):1014-9. PubMed ID: 26376466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving the Accuracy of Mesothelioma Diagnosis in China.
    Guo Z; Carbone M; Zhang X; Su D; Sun W; Lou J; Gao Z; Shao D; Chen J; Zhang G; Hu J; Chen K; Wang F; Pass HI; Yu H; Napolitano A; Yang H; Mao W
    J Thorac Oncol; 2017 Apr; 12(4):714-723. PubMed ID: 28007630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in pathological diagnosis of mesothelioma: what pulmonologists should know.
    Louw A; Badiei A; Creaney J; Chai MS; Lee YCG
    Curr Opin Pulm Med; 2019 Jul; 25(4):354-361. PubMed ID: 31169558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma.
    Ollila H; Paajanen J; Wolff H; Ilonen I; Sutinen E; Välimäki K; Östman A; Anttila S; Kettunen E; Räsänen J; Kallioniemi O; Myllärniemi M; Mäyränpää MI; Pellinen T
    J Pathol Clin Res; 2021 Sep; 7(5):482-494. PubMed ID: 33955203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.
    Negi Y; Kuribayashi K; Funaguchi N; Doi H; Mikami K; Minami T; Takuwa T; Yokoi T; Hasegawa S; Kijima T
    In Vivo; 2018; 32(5):1169-1174. PubMed ID: 30150440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathology of Malignant Pleural Mesothelioma.
    Hung YP; Chirieac LR
    Thorac Surg Clin; 2020 Nov; 30(4):367-382. PubMed ID: 33012427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pleurectomy-decortication in malignant pleural mesothelioma: are different surgical techniques associated with different outcomes? Results from a multicentre study.
    Marulli G; Breda C; Fontana P; Ratto GB; Leoncini G; Alloisio M; Infante M; Luzzi L; Paladini P; Oliaro A; Ruffini E; Benvenuti MR; Pariscenti G; Spaggiari L; Casiraghi M; Rusca M; Carbognani P; Ampollini L; Facciolo F; Leuzzi G; Mucilli F; Camplese P; Romanello P; Perissinotto E; Rea F
    Eur J Cardiothorac Surg; 2017 Jul; 52(1):63-69. PubMed ID: 28419212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
    Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
    Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.